 In this study, it was found that 42.5 percent of children with cystic fibrosis have bronchial hyperreactivity, BHR, to hypertonic salt solutions. This suggests that these children may not respond well to the standard treatment of inhaling hypertonic salt solutions, and could benefit from additional medication such as short-acting beta agonist drugs to help manage their symptoms. This article was authored by S. I. L. Chinco, A. O. Fiolkovska, K. V. Scriban, and others.